DBV Technologies Unveils Promising Data for Peanut Allergy Treatment
DBV Technologies, a clinical-stage biopharmaceutical company, is currently advancing a pipeline of investigational treatments for food allergies, centered on its proprietary epicutaneous immunotherapy (EPIT) technology. The firm, which was established by pediatricians, focuses on the development of the VIASKIN® patch, a device designed to re-educate the immune system by delivering minimal amounts of antigen through … Read more